top banner
美南廣場 / 董事長介紹

美國新冠疫情日記 09/18


美國新冠疫情日記 09/18






醫療專家不贊同打第三針


美國食品及藥物管理局週五否決輝瑞打第三針之申請,他們認為效果不大, 但對於六十或六十五歲以上之長者可能是需要。


委員會以十六對二票否決了輝瑞的申請,拜登政府本來是計劃在九月二十日開始實施施打第三針之计劃, 以阻止病毒之繼續蔓延, 與會人士認為, 這項決定過於傖促, 他們希望看到更多的證據我們需要打第三針, 而事實上還有許多人還拒絕施打, 也有人還沒有打第二針 ,醫療專家希望更多人能接種才能達到集體免疫之效果。


輝瑞製藥公司曾經依賴在以色列之資料, 顯示第三針才能制止更多之感染, 但是, 美國和以色列之國情大不相同, 不是每個人都要打第三針,除非是年長及患有疾病者。


我們是何等幸運能夠選擇打第三針,但也有許多拒絕打針的,他們選擇不相信科學,或者其他原因, 但是今天重病住院及死亡者, 多半是沒有接種疫苗的人, 這是何等之無知和難予置信的事呢。






FDA Rejects Pfizer’s Booster Application


The U.S. Food and Drug Administration (FDA) has rejected a vaccine booster application for approval of the use of booster doses of Pfizer’s vaccines in everyone 16 years old and older. Members of the FDA committee expressed doubts about the safety of a booster dose in young adults and teens six months after they are fully vaccinated and complained about the lack of data.


President Biden had previously announced a plan to begin administering booster doses to the general public the week of September 20th.


In a Friday meeting, experts wanted to have more data on the safety of booster doses in young adults and teens, but they believed boosters were likely necessary for a limited segment of the population.


The company in Israel that is relied upon for the data on the safety of booster doses said that adding booster shots will help keep people out of the hospital.


Pfizer has received full approval for its vaccine from the FDA. Their researchers said that people will develop strong immunity after two doses of the vaccine, but that the level of antibodies will start to drop after just a few months.


We are so lucky in America that everybody can get the vaccine shot, but we still have a lot of people who don’t want to take it. When we look at the record today, most people who got serious health problems and died are those people who don’t believe in the vaccine.


We still want to urge all our people to take action and get the vaccine shot as soon as possible.